Overview of the process This guideline adhered to international best practice for guideline development (Appendix B: Supplementary Tables S2 and S3).375,376 This guideline has been conducted and reported in accordance with the AGREE II reporting checklist.377 The processes under- taken for the development of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD are described below.  Appointing Work Group members and the ERT  Finalizing guideline development methodology  De ning scope and topics of the guideline  Formulating clinical questions identifying the Population, Intervention, Comparator, Outcome, Methods (PICOM)  Selecting topics for systematic evidence review and linking to existing Cochrane Kidney and Transplant systematic reviews  Developing and implementing literature search strategies  Selecting studies according to prede ned inclusion criteria  Data extraction and critical appraisal of the literature  Evidence synthesis and meta-analysis  Grading the quality of the evidence for each outcome across studies  Grading the strength of the recommendation, based on the quality of the evidence, and other considerations  Finalizing guideline recommendations and supporting rationale  Public review in January 2020  Guideline update  Finalizing and publishing the guideline The development process was followed in the majority of the guideline chapters. Some chapters, in particular Chapter 3, required an iterative process, whereby the initial evidence review deliverables were revised to re ect issues raised during the Work Group meeting in January 2019. These additional reviews and clari cations were provided to the Work Group coauthors to ensure that the draft of the Chapter re ected available evidence. Commissioning of Work Group and ERT. The KDIGO Co- Chairs appointed the Work Group Co-Chairs, who then assembled the Work Group, to include content experts in adult and pediatric nephrology, blood pressure management, epidemiology, and public health. 